All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
During the 63rd ASH Annual Meeting and Exposition, the MPN Hub was pleased to speak to Jean-Jacques Kiladjian, Université de Paris and Hôpital Saint-Louis, Paris, FR. We asked, ASH2021: What are the key highlights in MPN?
ASH2021: What are the key highlights in MPN?
In this video, Kiladjian highlights the key advances presented at ASH, particularly in regard to MPN treatment. Kiladjian discusses the JAK2 inhibitor fedratinib and the FREEDOM (NCT03755518) and FREEDOM2 (NCT03952039) trials. He also mentions pelabresib and the MANIFEST (NCT02158858) trial. Lastly, he comments on the lysine-specific histone demethylase-1 (LSD1) inhibitor bomedemstat, CD123-targeting agent tagraxofusp, and AVID200, a transforming growth factor-beta (TGF-beta) inhibitor.
Review of novel agents for myeloproliferative neoplasms
In the last 15 years, there have been rapid advances in understanding the importance and therapeutic potential of the Janus kinase/signal transducers and activators of transcription (JAK/STAT)...
Fedratinib in myelofibrosis
Fedratinib is a pyrimidine-based Janus kinase 2 (JAK2) inhibitor currently licenced by the U.S. Food and Drug Administration (FDA) for the treatment of adults with intermediate-2 or high-risk primary or secondary...
Subscribe to get the best content related to MPN delivered to your inbox